(untitled)Christina Yau, Adam L. Asare, Marie Osdoit et al.|Edinburgh Research Explorer|0Cited by 353
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancerAditya Bardia, Sara A. Hurvitz, Sabela Recalde et al.|Annals of Oncology|2021Cited by 294
Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline UpdateN. Lynn Henry, Angela DeMichele, Mark R. Somerfield et al.|Journal of Clinical Oncology|2022Cited by 127
Abstract GS3-00: First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25: SWOG S1007 (RxPonder)Kevin Kalinsky, Lajos Pusztai, William E. Barlow et al.|Cancer Research|2021Cited by 88
Letrozole + ribociclib versus letrozole + placebo as neoadjuvant therapy for ER+ breast cancer (FELINE trial).Qamar J. Khan, Priyanka Sharma, Anne O’Dea et al.|Journal of Clinical Oncology|2020Cited by 68